4//SEC Filing
First Eagle Value in Biotechnology Master Fund, Ltd. 4
Accession 0001140361-18-004372
CIK 0001001902other
Filed
Jan 31, 7:00 PM ET
Accepted
Feb 1, 2:18 PM ET
Size
20.7 KB
Accession
0001140361-18-004372
Insider Transaction Report
Form 4
INTEVAC INCIVAC
Transactions
- Purchase
Common Stock
2018-01-30$6.71/sh+13,298$89,207→ 4,403,035 total(indirect: See Footnote) - Purchase
Common Stock
2018-01-31$6.80/sh+19,485$132,479→ 4,435,920 total(indirect: See Footnote) - Other
Common Stock
2018-02-01−293,646→ 4,184,274 total(indirect: See Footnote) - Purchase
Common Stock
2018-01-30$6.83/sh+13,400$91,455→ 4,416,435 total(indirect: See Footnote) - Purchase
Common Stock
2018-01-31$6.85/sh+42,000$287,494→ 4,477,920 total(indirect: See Footnote)
21 APRIL FUND LTD
10% Owner
Transactions
- Purchase
Common Stock
2018-01-30$6.71/sh+13,298$89,207→ 4,403,035 total(indirect: See Footnote) - Purchase
Common Stock
2018-01-30$6.83/sh+13,400$91,455→ 4,416,435 total(indirect: See Footnote) - Purchase
Common Stock
2018-01-31$6.85/sh+42,000$287,494→ 4,477,920 total(indirect: See Footnote) - Purchase
Common Stock
2018-01-31$6.80/sh+19,485$132,479→ 4,435,920 total(indirect: See Footnote) - Other
Common Stock
2018-02-01−293,646→ 4,184,274 total(indirect: See Footnote)
Transactions
- Purchase
Common Stock
2018-01-30$6.83/sh+13,400$91,455→ 4,416,435 total(indirect: See Footnote) - Purchase
Common Stock
2018-01-31$6.80/sh+19,485$132,479→ 4,435,920 total(indirect: See Footnote) - Purchase
Common Stock
2018-01-31$6.85/sh+42,000$287,494→ 4,477,920 total(indirect: See Footnote) - Purchase
Common Stock
2018-01-30$6.71/sh+13,298$89,207→ 4,403,035 total(indirect: See Footnote) - Other
Common Stock
2018-02-01−293,646→ 4,184,274 total(indirect: See Footnote)
Transactions
- Other
Common Stock
2018-02-01−293,646→ 4,184,274 total(indirect: See Footnote) - Purchase
Common Stock
2018-01-30$6.83/sh+13,400$91,455→ 4,416,435 total(indirect: See Footnote) - Purchase
Common Stock
2018-01-31$6.85/sh+42,000$287,494→ 4,477,920 total(indirect: See Footnote) - Purchase
Common Stock
2018-01-30$6.71/sh+13,298$89,207→ 4,403,035 total(indirect: See Footnote) - Purchase
Common Stock
2018-01-31$6.80/sh+19,485$132,479→ 4,435,920 total(indirect: See Footnote)
Footnotes (8)
- [F1]This Form 4 is filed by 21 April Ltd. ("April Ltd."), First Eagle Investment Management, LLC ("FEIM"), First Eagle Value in Biotechnology Master Fund, Ltd. ("FEVIBM") and First Eagle Holdings, Inc. ("FEHI" and, collectively with April Ltd., FEIM and FEVIBM, the "Entities"). The Entities disclaim status as a "group" for purposes of this Form 4.
- [F2]The shares of Common Stock reported herein are indirectly beneficially owned by FEHI and FEIM, a Delaware limited liability company and an investment adviser registered under the Investment Advisers Act of 1940. FEIM is (i) the registered investment adviser to FEVIBM as well as to April Ltd. (collectively, the "Funds"), (ii) a subsidiary of FEHI and (iii) investment adviser to certain separately managed accounts which, together with certain separate accounts managed by Michael M. Kellen in his individual capacity holding shares reported by FEIM for which FEIM disclaims beneficial ownership are defined herein as the "Separately Managed Accounts". FEHI disclaims Section 16 beneficial ownership of the shares held directly by the Funds except to the extent, if any, of its pecuniary interest therein, and this report shall not be deemed an admission that FEHI is the Section 16 beneficial owner of any such securities.
- [F3]Represents 2,611,069, 299,662 and 1,492,304 shares held directly by 21 April Ltd., FEVIBM and the Separately Managed Accounts, respectively. FEHI disclaims Section 16 beneficial ownership of the shares held directly by the Funds except to the extent, if any, of its pecuniary interest therein, and this report shall not be deemed an admission that FEHI is the Section 16 beneficial owner of any such securities.
- [F4]Represents 2,622,888, 299,662 and 1,493,885 shares held directly by 21 April Ltd., FEVIBM and the Separately Managed Accounts, respectively. FEHI disclaims Section 16 beneficial ownership of the shares held directly by the Funds except to the extent, if any, of its pecuniary interest therein, and this report shall not be deemed an admission that FEHI is the Section 16 beneficial owner of any such securities.
- [F5]Represents 2,640,074, 299,662 and 1,496,184 shares held directly by 21 April Ltd., FEVIBM and the Separately Managed Accounts, respectively. FEHI disclaims Section 16 beneficial ownership of the shares held directly by the Funds except to the extent, if any, of its pecuniary interest therein, and this report shall not be deemed an admission that FEHI is the Section 16 beneficial owner of any such securities.
- [F6]Represents 2,677,118, 299,662 and 1,501,140 shares held directly by 21 April Ltd., FEVIBM and the Separately Managed Accounts, respectively. FEHI disclaims Section 16 beneficial ownership of the shares held directly by the Funds except to the extent, if any, of its pecuniary interest therein, and this report shall not be deemed an admission that FEHI is the Section 16 beneficial owner of any such securities.
- [F7]As of February 1, 2018, certain separately managed accounts terminated their relationship with, and are no longer advised by, FEIM. The positions held in such accounts are therefore no longer included herein.
- [F8]Represents 2,677,118, 299,662 and 1,207,494 shares held directly by 21 April Ltd., FEVIBM and the Separately Managed Accounts, respectively. FEHI disclaims Section 16 beneficial ownership of the shares held directly by the Funds except to the extent, if any, of its pecuniary interest therein, and this report shall not be deemed an admission that FEHI is the Section 16 beneficial owner of any such securities.
Documents
Issuer
INTEVAC INC
CIK 0001001902
Entity typeother
Related Parties
1- filerCIK 0001457518
Filing Metadata
- Form type
- 4
- Filed
- Jan 31, 7:00 PM ET
- Accepted
- Feb 1, 2:18 PM ET
- Size
- 20.7 KB